BCR-ABL1 Quantitative RT-PCR: Blood RNA/DNA Extraction for CML Monitoring

BCR-ABL by quantitative PCR is a molecular test that measures the amount of BCR-ABL1 fusion transcript in a patient sample, usually from blood. It is widely used to monitor chronic myeloid leukemia treatment response over time. Reliable results depend on high-quality RNA extraction, low contamination, and reproducible downstream amplification and quantification.

Blood RNA extraction is critical because BCR-ABL1 quantitative RT-PCR measures fusion transcripts at the RNA level. Poor RNA quality, degradation, or DNA contamination can affect assay sensitivity and reproducibility. Automated magnetic bead-based workflows with DNase treatment help preserve transcript integrity, improve consistency, and support dependable longitudinal monitoring in molecular laboratories.

Yes. While BCR-ABL1 quantitative RT-PCR primarily relies on RNA, DNA extraction can support complementary molecular workflows such as confirmatory PCR assays, sequencing, or broader genetic testing in hematologic oncology. Whole blood gDNA kits with consistent purity and rapid processing can fit into labs that run both transcript-based monitoring and additional genomic analyses.

Within this category, the primary sample type for CML monitoring workflows is whole blood. The RNA kit is designed for whole blood input from 500 µL to 2 mL, while the gDNA kit supports whole blood and additional sample types in broader workflows. For blood-based BCR-ABL1 monitoring, whole blood compatibility is the key consideration.

The whole blood RNA workflow runs with a 50-minute on-deck time, while the whole blood gDNA workflow completes in under 30 minutes. These automated, cartridge-based processes reduce manual handling and help labs improve turnaround time. Faster extraction can be especially valuable for oncology and molecular diagnostics labs managing routine monitoring volumes.

Important features include magnetic bead-based purification, integrated or included DNase treatment, pre-filled cartridges, non-reusable consumables to reduce cross-contamination, and automation on a standardized platform. For RNA workflows, high integrity metrics such as RIN 8.6–9.7 and cleaner extracts are especially useful for sensitive downstream applications like BCR-ABL1 quantitative RT-PCR.